p38α MAPK pathway: A key factor in colorectal cancer therapy and chemoresistance

World Journal of Gastroenterology

Volumn , Issue 29, 2014, Pages 9744-9758

  Grossi, Valentina ^a,b   Peserico, Alessia ^a,b,c   Tezil, Tugsan ^a,b   Simone, Cristiano ^a,b  

^a UNIVERSITY OF BARI   (Italy)

^b NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^c MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

Cell death; Chemoresistance; Colorectal cancer; Molecularly targeted drugs; p38 mitogen activated protein kinase

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 HYDROXYPHENYL) 5 (4 PYRIDYL) IMIDAZOLE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL) IMIDAZOLE; BAFILOMYCIN; BEVACIZUMAB; CETUXIMAB; CISPLATIN; CYCLOOXYGENASE 2; DORAMAPIMOD; FLUOROURACIL; FOLINIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IRINOTECAN; MITOGEN ACTIVATED PROTEIN KINASE 14; MULTIDRUG RESISTANCE PROTEIN; PANITUMUMAB; PROTEIN BAX; REGORAFENIB; SORAFENIB; TRANSCRIPTION FACTOR FKHRL1; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR;

ANGIOGENESIS; APOPTOSIS; AUTOPHAGY; CARCINOGENESIS; CELL CYCLE PROGRESSION; CELL CYCLE REGULATION; CELL METABOLISM; CLINICAL TRIAL (TOPIC); COLORECTAL CANCER; DNA DAMAGE; DRUG EFFICACY; GENE; GENE EXPRESSION; GENOMIC INSTABILITY; HUMAN; INFLAMMATION; MALIGNANT TRANSFORMATION; METASTASIS; MOLECULAR INTERACTION; MOLECULARLY TARGETED THERAPY; NONHUMAN; PERSONALIZED MEDICINE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; TUMOR INVASION; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL TRANSFORMATION; COLORECTAL NEOPLASMS; DRUG EFFECTS; DRUG RESISTANCE; ENZYMOLOGY; METABOLISM; PATHOLOGY; TREATMENT OUTCOME; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER STEM CELL; CELL DEATH; CELL DIFFERENTIATION; CELL GROWTH; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; COLON CARCINOGENESIS; INTESTINAL STEM CELL; OVERALL SURVIVAL; PROTEIN EXPRESSION; QUALITY OF LIFE; TREATMENT RESPONSE;

ANIMALS; ANTINEOPLASTIC AGENTS; AUTOPHAGY; CELL TRANSFORMATION, NEOPLASTIC; COLORECTAL NEOPLASMS; DRUG RESISTANCE, NEOPLASM; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASE 14; MOLECULAR TARGETED THERAPY; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 84905864449     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i29.9744     Document Type: Review

References (165)

1. Kemp Z, Thirlwell C, Sieber O, Silver A, Tomlinson I. An update on the genetics of colorectal cancer. Hum Mol Genet 2004; 13 Spec No 2: R177-R185 [PMID: 15358723 DOI: 10.1093/hmg/ddh247]
2. Zhang ZG, Harstrick A, Rustum YM. Mechanisms of resistance to fluoropyrimidines. Semin Oncol 1992; 19: 4-9 [PMID: 1532673]
3. Petrelli N, Douglass HO, Herrera L, Russell D, Stablein DM, Bruckner HW, Mayer RJ, Schinella R, Green MD, Muggia FM. The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. Gastrointestinal Tumor Study Group. J Clin Oncol 1989; 7: 1419-1426 [PMID: 2674331]
4. Rabik CA, Dolan ME. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 2007; 33: 9-23 [PMID: 17084534 DOI: 10.1016/j.ctrv.2006.09.006]
5. Willett CG, Duda DG, di Tomaso E, Boucher Y, Ancukiewicz M, Sahani DV, Lahdenranta J, Chung DC, Fischman AJ, Lauwers GY, Shellito P, Czito BG, Wong TZ, Paulson E, Poleski M, Vujaskovic Z, Bentley R, Chen HX, Clark JW, Jain RK. Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. J Clin Oncol 2009; 27: 3020-3026 [PMID: 19470921 DOI: 10.1200/JCO.2008.21.1771]
6. Kyriakis JM, Avruch J. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol Rev 2001; 81: 807-869 [PMID: 11274345]
7. Kyriakis JM, Avruch J. Mammalian MAPK signal transduction pathways activated by stress and inflammation: a 10-year update. Physiol Rev 2012; 92: 689-737 [PMID: 22535895 DOI: 10.1152/physrev.00028.2011]
8. Reményi A, Good MC, Bhattacharyya RP, Lim WA. The role of docking interactions in mediating signaling input, output, and discrimination in the yeast MAPK network. Mol Cell 2005; 20: 951-962 [PMID: 16364919 DOI: 10.1016/j.molcel.2005.10.030]
9. Jacobs D, Glossip D, Xing H, Muslin AJ, Kornfeld K. Multiple docking sites on substrate proteins form a modular system that mediates recognition by ERK MAP kinase. Genes Dev 1999; 13: 163-175 [PMID: 9925641]
10. Biondi RM, Nebreda AR. Signalling specificity of Ser/Thr protein kinases through docking-site-mediated interactions. Biochem J 2003; 372: 1-13 [PMID: 12600273 DOI: 10.1042/BJ20021641]
11. Rouse J, Cohen P, Trigon S, Morange M, Alonso-Llamazares A, Zamanillo D, Hunt T, Nebreda AR. A novel kinase cascade triggered by stress and heat shock that stimulates MAPKAP kinase-2 and phosphorylation of the small heat shock proteins. Cell 1994; 78: 1027-1037 [PMID: 7923353 DOI: 10.1016/0092-8674(94)90277-1]
12. Han SJ, Choi KY, Brey PT, Lee WJ. Molecular cloning and characterization of a Drosophila p38 mitogen-activated protein kinase. J Biol Chem 1998; 273: 369-374 [PMID: 9417090 DOI: 10.1074/jbc.273.1.369]
13. Shiozaki K, Russell P. Cell-cycle control linked to extracellular environment by MAP kinase pathway in fission yeast. Nature 1995; 378: 739-743 [PMID: 7501024 DOI: 10.1038/378739a0]
14. Brewster JL, de Valoir T, Dwyer ND, Winter E, Gustin MC. An osmosensing signal transduction pathway in yeast. Science 1993; 259: 1760-1763 [PMID: 7681220 DOI: 10.1126/science.7681220]
15. Shiozaki K, Russell P. Conjugation, meiosis, and the osmotic stress response are regulated by Spc1 kinase through Atf1 transcription factor in fission yeast. Genes Dev 1996; 10: 2276-2288 [PMID: 8824587 DOI: 10.1101/gad.10.18.2276]
16. Wagner EF, Nebreda AR. Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer 2009; 9: 537-549 [PMID: 19629069 DOI: 10.1038/nrc2694]
17. Chiacchiera F, Simone C. Signal-dependent regulation of gene expression as a target for cancer treatment: inhibiting p38alpha in colorectal tumors. Cancer Lett 2008; 265: 16-26 [PMID: 18395970 DOI: 10.1016/j.canlet.2008.02.061]
18. Cuadrado A, Nebreda AR. Mechanisms and functions of p38 MAPK signalling. Biochem J 2010; 429: 403-417 [PMID: 20626350 DOI: 10.1042/BJ20100323]
19. Cuenda A, Rousseau S. p38 MAP-kinases pathway regulation, function and role in human diseases. Biochim Biophys Acta 2007; 1773: 1358-1375 [PMID: 17481747 DOI: 10.1016/j.bbamcr.2007.03.010]
20. Vachon PH, Harnois C, Grenier A, Dufour G, Bouchard V, Han J, Landry J, Beaulieu JF, Vézina A, Dydensborg AB, Gauthier R, Côté A, Drolet JF, Lareau F. Differentiation state-selective roles of p38 isoforms in human intestinal epithelial cell anoikis. Gastroenterology 2002; 123: 1980-1991 [PMID: 12454855]
21. Comes F, Matrone A, Lastella P, Nico B, Susca FC, Bagnulo R, Ingravallo G, Modica S, Lo Sasso G, Moschetta A, Guanti G, Simone C. A novel cell type-specific role of p38alpha in the control of autophagy and cell death in colorectal cancer cells. Cell Death Differ 2007; 14: 693-702 [PMID: 17159917 DOI: 10.1038/sj.cdd.4402076]
22. Lee JC, Laydon JT, McDonnell PC, Gallagher TF, Kumar S, Green D, McNulty D, Blumenthal MJ, Heys JR, Landvatter SW. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 1994; 372: 739-746 [PMID: 7997261 DOI: 10.1038/372739a0]
23. Sanz V, Arozarena I, Crespo P. Distinct carboxy- termini confer divergent characteristics to the mitogen-activated protein kinase p38α and its splice isoform Mxi2. FEBS Lett 2000; 474: 169-174
24. Casar B, Sanz-Moreno V, Yazicioglu MN, Rodríguez J, Berciano MT, Lafarga M, Cobb MH, Crespo P. Mxi2 promotes stimulus-independent ERK nuclear translocation. EMBO J 2007; 26: 635-646 [PMID: 17255949 DOI: 10.1038/sj.emboj.7601523]
25. Yagasaki Y, Sudo T, Osada H. Exip, a splicing variant of p38alpha, participates in interleukin-1 receptor proximal complex and downregulates NF-kappaB pathway. FEBS Lett 2004; 575: 136-140 [PMID: 15388348]
26. Im JS, Lee JK. ATR-dependent activation of p38 MAP kinase is responsible for apoptotic cell death in cells depleted of Cdc7. J Biol Chem 2008; 283: 25171-25177 [PMID: 18625709 DOI: 10.1074/jbc.M802851200]
27. Salvador JM, Mittelstadt PR, Belova GI, Fornace AJ, Ashwell JD. The autoimmune suppressor Gadd45alpha inhibits the T cell alternative p38 activation pathway. Nat Immunol 2005; 6: 396-402 [PMID: 15735649 DOI: 10.1038/ni1176]
28. Zhang F, Strand A, Robbins D, Cobb MH, Goldsmith EJ. Atomic structure of the MAP kinase ERK2 at 2.3 A resolution. Nature 1994; 367: 704-711 [PMID: 8107865 DOI: 10.1038/367704a0]
29. Wilson KP, Fitzgibbon MJ, Caron PR, Griffith JP, Chen W, McCaffrey PG, Chambers SP, Su MS. Crystal structure of p38 mitogen-activated protein kinase. J Biol Chem 1996; 271: 27696-27700 [PMID: 8910361]
30. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674 [PMID: 21376230]
31. Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, Bignell G, Davies H, Teague J, Butler A, Stevens C, Edkins S, O'Meara S, Vastrik I, Schmidt EE, Avis T, Barthorpe S, Bhamra G, Buck G, Choudhury B, Clements J, Cole J, Dicks E, Forbes S, Gray K, Halliday K, Harrison R, Hills K, Hinton J, Jenkinson A, Jones D, Menzies A, Mironenko T, Perry J, Raine K, Richardson D, Shepherd R, Small A, Tofts C, Varian J, Webb T, West S, Widaa S, Yates A, Cahill DP, Louis DN, Goldstraw P, Nicholson AG, Brasseur F, Looijenga L, Weber BL, Chiew YE, DeFazio A, Greaves MF, Green AR, Campbell P, Birney E, Easton DF, Chenevix-Trench G, Tan MH, Khoo SK, Teh BT, Yuen ST, Leung SY, Wooster R, Futreal PA, Stratton MR. Patterns of somatic mutation in human cancer genomes. Nature 2007; 446: 153-158 [PMID: 17344846]
32. Wood LD, Parsons DW, Jones S, Lin J, Sjöblom T, Leary RJ, Shen D, Boca SM, Barber T, Ptak J, Silliman N, Szabo S, Dezso Z, Ustyanksky V, Nikolskaya T, Nikolsky Y, Karchin R, Wilson PA, Kaminker JS, Zhang Z, Croshaw R, Willis J, Dawson D, Shipitsin M, Willson JK, Sukumar S, Polyak K, Park BH, Pethiyagoda CL, Pant PV, Ballinger DG, Sparks AB, Hartigan J, Smith DR, Suh E, Papadopoulos N, Buckhaults P, Markowitz SD, Parmigiani G, Kinzler KW, Velculescu VE, Vogelstein B. The genomic landscapes of human breast and colorectal cancers. Science 2007; 318: 1108-1113 [PMID: 17932254]
33. Brozovic A, Osmak M. Activation of mitogen-activated protein kinases by cisplatin and their role in cisplatin-resistance. Cancer Lett 2007; 251: 1-16 [PMID: 17125914]
34. Ciesielski-Treska J, Ulrich G, Chasserot-Golaz S, Zwiller J, Revel MO, Aunis D, Bader MF. Mechanisms underlying neuronal death induced by chromogranin A-activated microglia. J Biol Chem 2001; 276: 13113-13120 [PMID: 11124958]
35. De Zutter GS, Davis RJ. Pro-apoptotic gene expression mediated by the p38 mitogen-activated protein kinase signal transduction pathway. Proc Natl Acad Sci USA 2001; 98: 6168-6173 [PMID: 11344273]
36. Ghatan S, Larner S, Kinoshita Y, Hetman M, Patel L, Xia Z, Youle RJ, Morrison RS. p38 MAP kinase mediates bax translocation in nitric oxide-induced apoptosis in neurons. J Cell Biol 2000; 150: 335-347 [PMID: 10908576]
37. Le-Niculescu H, Bonfoco E, Kasuya Y, Claret FX, Green DR, Karin M. Withdrawal of survival factors results in activation of the JNK pathway in neuronal cells leading to Fas ligand induction and cell death. Mol Cell Biol 1999; 19: 751-763 [PMID: 9858598]
38. Mackay K, Mochly-Rosen D. An inhibitor of p38 mitogen-ctivated protein kinase protects neonatal cardiac myocytes from ischemia. J Biol Chem 1999; 274: 6272-6279 [PMID: 10037715]
39. Saurin AT, Martin JL, Heads RJ, Foley C, Mockridge JW, Wright MJ, Wang Y, Marber MS. The role of differential activation of p38-mitogen-activated protein kinase in preconditioned ventricular myocytes. FASEB J 2000; 14: 2237-2246 [PMID: 11053245]
40. Wang Y, Huang S, Sah VP, Ross J, Brown JH, Han J, Chien KR. Cardiac muscle cell hypertrophy and apoptosis induced by distinct members of the p38 mitogen-activated protein kinase family. J Biol Chem 1998; 273: 2161-2168 [PMID: 9442057]
41. Valladares A, Alvarez AM, Ventura JJ, Roncero C, Benito M, Porras A. p38 mitogen-activated protein kinase mediates tumor necrosis factor-alpha-induced apoptosis in rat fetal brown adipocytes. Endocrinology 2000; 141: 4383-4395 [PMID: 11108246]
42. Edlund S, Bu S, Schuster N, Aspenström P, Heuchel R, Heldin NE, ten Dijke P, Heldin CH, Landström M. Transforming growth factor-beta1 (TGF-beta)-induced apoptosis of prostate cancer cells involves Smad7-dependent activation of p38 by TGF-beta-activated kinase 1 and mitogen-activated protein kinase kinase 3. Mol Biol Cell 2003; 14: 529-544 [PMID: 12589052]
43. Zhuang S, Demirs JT, Kochevar IE. p38 mitogen-activated protein kinase mediates bid cleavage, mitochondrial dysfunction, and caspase-3 activation during apoptosis induced by singlet oxygen but not by hydrogen peroxide. J Biol Chem 2000; 275: 25939-25948 [PMID: 10837470]
44. Porras A, Zuluaga S, Black E, Valladares A, Alvarez AM, Ambrosino C, Benito M, Nebreda AR. P38 alpha mitogen-activated protein kinase sensitizes cells to apoptosis induced by different stimuli. Mol Biol Cell 2004; 15: 922-933 [PMID: 14617800 DOI: 10.1091/mbc.E03-08-0592]
45. Zuluaga S, Alvarez-Barrientos A, Gutiérrez-Uzquiza A, Benito M, Nebreda AR, Porras A. Negative regulation of Akt activity by p38alpha MAP kinase in cardiomyocytes involves membrane localization of PP2A through interaction with caveolin-1. Cell Signal 2007; 19: 62-74 [PMID: 16844343 DOI: 10.1016/j.cellsig.2006.05.032]
46. Nebreda AR, Porras A. p38 MAP kinases: beyond the stress response. Trends Biochem Sci 2000; 25: 257-260 [PMID: 10838561 DOI: 10.1016/S0968-0004(00)01595-4]
47. Ventura JJ, Tenbaum S, Perdiguero E, Huth M, Guerra C, Barbacid M, Pasparakis M, Nebreda AR. p38alpha MAP kinase is essential in lung stem and progenitor cell proliferation and differentiation. Nat Genet 2007; 39: 750-758 [PMID: 17468755 DOI: 10.1038/ng2037]
48. Brancho D, Tanaka N, Jaeschke A, Ventura JJ, Kelkar N, Tanaka Y, Kyuuma M, Takeshita T, Flavell RA, Davis RJ. Mechanism of p38 MAP kinase activation in vivo. Genes Dev 2003; 17: 1969-1978 [PMID: 12893778 DOI: 10.1101/gad.1107303]
49. Bulavin DV, Phillips C, Nannenga B, Timofeev O, Donehower LA, Anderson CW, Appella E, Fornace AJ. Inactivation of the Wip1 phosphatase inhibits mammary tumorigenesis through p38 MAPK-mediated activation of the p16(Ink4a)-p19(Arf) pathway. Nat Genet 2004; 36: 343-350 [PMID: 14991053 DOI: 10.1038/ng1317]
50. Tront JS, Hoffman B, Liebermann DA. Gadd45a suppresses Ras-driven mammary tumorigenesis by activation of c-Jun NH2-terminal kinase and p38 stress signaling resulting in apoptosis and senescence. Cancer Res 2006; 66: 8448-8454 [PMID: 16951155 DOI: 10.1158/0008-5472.CAN-06-2013]
51. Bulavin DV, Demidov ON, Saito S, Kauraniemi P, Phillips C, Amundson SA, Ambrosino C, Sauter G, Nebreda AR, Anderson CW, Kallioniemi A, Fornace AJ, Appella E. Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity. Nat Genet 2002; 31: 210-215 [PMID: 12021785 DOI: 10.1038/ng894]
52. Li J, Yang Y, Peng Y, Austin RJ, van Eyndhoven WG, Nguyen KC, Gabriele T, McCurrach ME, Marks JR, Hoey T, Lowe SW, Powers S. Oncogenic properties of PPM1D located within a breast cancer amplification epicenter at 17q23. Nat Genet 2002; 31: 133-134 [PMID: 12021784 DOI: 10.1038/ng888]
53. Yu W, Imoto I, Inoue J, Onda M, Emi M, Inazawa J. A novel amplification target, DUSP26, promotes anaplastic thyroid cancer cell growth by inhibiting p38 MAPK activity. Oncogene 2007; 26: 1178-1187 [PMID: 16924234 DOI: 10.1038/sj.onc.1209899]
54. Li SP, Junttila MR, Han J, Kähäri VM, Westermarck J. p38 Mitogen-activated protein kinase pathway suppresses cell survival by inducing dephosphorylation of mitogen-activated protein/extracellular signal-regulated kinase kinase1,2. Cancer Res 2003; 63: 3473-3477 [PMID: 12839928]
55. Wang W, Chen JX, Liao R, Deng Q, Zhou JJ, Huang S, Sun P. Sequential activation of the MEK-extracellular signal-regulated kinase and MKK3/6-p38 mitogen-activated protein kinase pathways mediates oncogenic ras-induced premature senescence. Mol Cell Biol 2002; 22: 3389-3403 [PMID: 11971971 DOI: 10.1128/MCB.22.10.3389-3403.2002]
56. Nicke B, Bastien J, Khanna SJ, Warne PH, Cowling V, Cook SJ, Peters G, Delpuech O, Schulze A, Berns K, Mullenders J, Beijersbergen RL, Bernards R, Ganesan TS, Downward J, Hancock DC. Involvement of MINK, a Ste20 family kinase, in Ras oncogene-induced growth arrest in human ovarian surface epithelial cells. Mol Cell 2005; 20: 673-685 [PMID: 16337592 DOI: 10.1016/j.molcel.2005.10.038]
57. Wolfman JC, Palmby T, Der CJ, Wolfman A. Cellular N-Ras promotes cell survival by downregulation of Jun N-terminal protein kinase and p38. Mol Cell Biol 2002; 22: 1589-1606 [PMID: 11839824 DOI: 10.1128/MCB.22.5.1589-1606.2002]
58. Qi X, Tang J, Pramanik R, Schultz RM, Shirasawa S, Sasazuki T, Han J, Chen G. p38 MAPK activation selectively induces cell death in K-ras-mutated human colon cancer cells through regulation of vitamin D receptor. J Biol Chem 2004; 279: 22138-22144 [PMID: 15037631 DOI: 10.1074/jbc.M313964200]
59. Dolado I, Swat A, Ajenjo N, De Vita G, Cuadrado A, Nebreda AR. p38alpha MAP kinase as a sensor of reactive oxygen species in tumorigenesis. Cancer Cell 2007; 11: 191-205 [PMID: 17292829 DOI: 10.1016/j.ccr.2006.12.013]
60. Hui L, Bakiri L, Mairhorfer A, Schweifer N, Haslinger C, Kenner L, Komnenovic V, Scheuch H, Beug H, Wagner EF. p38alpha suppresses normal and cancer cell proliferation by antagonizing the JNK-c-Jun pathway. Nat Genet 2007; 39: 741-749 [PMID: 17468757 DOI: 10.1038/ng2033]
61. Voisset E, Oeztuerk-Winder F, Ruiz EJ, Ventura JJ. p38α negatively regulates survival and malignant selection of transformed bronchioalveolar stem cells. PLoS One 2013; 8: e78911 [PMID: 24265727 DOI: 10.1371/journal.pone.0078911]
62. Esteva FJ, Sahin AA, Smith TL, Yang Y, Pusztai L, Nahta R, Buchholz TA, Buzdar AU, Hortobagyi GN, Bacus SS. Prognostic significance of phosphorylated P38 mitogen-activated protein kinase and HER-2 expression in lymph nodepositive breast carcinoma. Cancer 2004; 100: 499-506 [PMID: 14745865 DOI: 10.1002/cncr.11940]
63. Wang SN, Lee KT, Tsai CJ, Chen YJ, Yeh YT. Phosphorylated p38 and JNK MAPK proteins in hepatocellular carcinoma. Eur J Clin Invest 2012; 42: 1295-1301 [PMID: 23033928 DOI: 10.1111/eci.12003]
64. Matrone A, Grossi V, Chiacchiera F, Fina E, Cappellari M, Caringella AM, Di Naro E, Loverro G, Simone C. p38alpha is required for ovarian cancer cell metabolism and survival. Int J Gynecol Cancer 2010; 20: 203-211 [PMID: 20169663]
65. Grossi V, Simone C. Special Agents Hunting Down Women Silent Killer: The Emerging Role of the p38α Kinase. J Oncol 2012; 2012: 382159 [PMID: 22481926 DOI: 10.1155/2012/382159]
66. Junttila MR, Ala-aho R, Jokilehto T, Peltonen J, Kallajoki M, Grenman R, Jaakkola P, Westermarck J, Kähäri VM. p38α and p38α mitogen-activated protein kinase isoforms regulate invasion and growth of head and neck squamous carcinoma cells. Oncogene 2007; 26: 5267-5279 [DOI: 10.1038/sj.onc.1210332]
67. Bakin AV, Rinehart C, Tomlinson AK, Arteaga CL. p38 mitogen-activated protein kinase is required for TGFbeta-mediated fibroblastic transdifferentiation and cell migration. J Cell Sci 2002; 115: 3193-3206 [PMID: 12118074]
68. Hsieh YH, Wu TT, Huang CY, Hsieh YS, Hwang JM, Liu JY. p38 mitogen-activated protein kinase pathway is involved in protein kinase Calpha-regulated invasion in human hepatocellular carcinoma cells. Cancer Res 2007; 67: 4320-4327 [PMID: 17483345]
69. Kim MS, Lee EJ, Kim HR, Moon A. p38 kinase is a key signaling molecule for H-Ras-induced cell motility and invasive phenotype in human breast epithelial cells. Cancer Res 2003; 63: 5454-5461 [PMID: 14500381]
70. Chen L, Mayer JA, Krisko TI, Speers CW, Wang T, Hilsenbeck SG, Brown PH. Inhibition of the p38 kinase suppresses the proliferation of human ER-negative breast cancer cells. Cancer Res 2009; 69: 8853-8861 [PMID: 19920204]
71. Chiacchiera F, Simone C. Inhibition of p38alpha unveils an AMPK-FoxO3A axis linking autophagy to cancer-specific metabolism. Autophagy 2009; 5: 1030-1033 [PMID: 19587525]
72. Ricote M, García-Tuñón I, Bethencourt F, Fraile B, Onsurbe P, Paniagua R, Royuela M. The p38 transduction pathway in prostatic neoplasia. J Pathol 2006; 208: 401-407 [PMID: 16369914]
73. Schindler EM, Hindes A, Gribben EL, Burns CJ, Yin Y, Lin MH, Owen RJ, Longmore GD, Kissling GE, Arthur JS, Efimova T. p38delta Mitogen-activated protein kinase is essential for skin tumor development in mice. Cancer Res 2009; 69: 4648-4655 [PMID: 19458068]
74. Emerling BM, Platanias LC, Black E, Nebreda AR, Davis RJ, Chandel NS. Mitochondrial reactive oxygen species activation of p38 mitogen-activated protein kinase is required for hypoxia signaling. Mol Cell Biol 2005; 25: 4853-4862 [PMID: 15923604 DOI: 10.1128/MCB.25.12.4853-4862.2005]
75. Halawani D, Mondeh R, Stanton LA, Beier F. p38 MAP kinase signaling is necessary for rat chondrosarcoma cell proliferation. Oncogene 2004; 23: 3726-3731 [PMID: 15116104 DOI: 10.1038/sj.onc.1207422]
76. Adam AP, George A, Schewe D, Bragado P, Iglesias BV, Ranganathan AC, Kourtidis A, Conklin DS, Aguirre-Ghiso JA. Computational identification of a p38SAPK-regulated transcription factor network required for tumor cell quiescence. Cancer Res 2009; 69: 5664-5672 [PMID: 19584293 DOI: 10.1158/0008-5472.CAN-08-3820]
77. Chiacchiera F, Grossi V, Cappellari M, Peserico A, Simonatto M, Germani A, Russo S, Moyer MP, Resta N, Murzilli S, Simone C. Blocking p38/ERK crosstalk affects colorectal cancer growth by inducing apoptosis in vitro and in preclinical mouse models. Cancer Lett 2012; 324: 98-108 [PMID: 22579651 DOI: 10.1016/j.canlet.2012.05.006]
78. Kroemer G, Levine B. Autophagic cell death: the story of a misnomer. Nat Rev Mol Cell Biol 2008; 9: 1004-1010 [PMID: 18971948 DOI: 10.1038/nrm2529]
79. Mizushima N. Autophagy: process and function. Genes Dev 2007; 21: 2861-2873 [PMID: 18006683 DOI: 10.1101/gad.1599207]
80. Levine B, Kroemer G. Autophagy in the pathogenesis of disease. Cell 2008; 132: 27-42 [PMID: 18191218 DOI: 10.1016/j.cell.2007.12.018]
81. Adams JM, Cory S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 2007; 26: 1324-1337 [PMID: 17322918 DOI: 10.1038/sj.onc.1210220]
82. White E, Lowe SW. Eating to exit: autophagy-enabled senescence revealed. Genes Dev 2009; 23: 784-787 [PMID: 19339684 DOI: 10.1101/gad.1795309]
83. White E, DiPaola RS. The double-edged sword of autophagy modulation in cancer. Clin Cancer Res 2009; 15: 5308-5316 [PMID: 19706824 DOI: 10.1158/1078-0432.CCR-07-5023]
84. Mathew R, Karantza-Wadsworth V, White E. Role of autophagy in cancer. Nat Rev Cancer 2007; 7: 961-967 [PMID: 17972889 DOI: 10.1038/nrc2254]
85. Ranganathan AC, Adam AP, Aguirre-Ghiso JA. Opposing roles of mitogenic and stress signaling pathways in the induction of cancer dormancy. Cell Cycle 2006; 5: 1799-1807 [PMID: 16929185 DOI: 10.4161/cc.5.16.3109]
86. Simone C. Signal-dependent control of autophagy and cell death in colorectal cancer cell: the role of the p38 pathway. Autophagy 2007; 3: 468-471 [PMID: 17495519]
87. Madia F, Grossi V, Peserico A, Simone C. Updates from the Intestinal Front Line: Autophagic Weapons against Inflammation and Cancer. Cells 2012; 1: 535-557 [PMID: 24710489 DOI: 10.3390/cells1030535]
88. Chiacchiera F, Matrone A, Ferrari E, Ingravallo G, Lo Sasso G, Murzilli S, Petruzzelli M, Salvatore L, Moschetta A, Simone C. p38alpha blockade inhibits colorectal cancer growth in vivo by inducing a switch from HIF1alpha- to FoxO-dependent transcription. Cell Death Differ 2009; 16: 1203-1214 [PMID: 19343039 DOI: 10.1038/cdd.2009.36]
89. Webber JL, Tooze SA. Coordinated regulation of autophagy by p38alpha MAPK through mAtg9 and p38IP. EMBO J 2010; 29: 27-40 [PMID: 19893488 DOI: 10.1038/emboj.2009.321]
90. vom Dahl S, Dombrowski F, Schmitt M, Schliess F, Pfeifer U, Häussinger D. Cell hydration controls autophagosome formation in rat liver in a microtubule-dependent way downstream from p38MAPK activation. Biochem J 2001; 354: 31-36 [PMID: 11171076]
91. Corcelle E, Djerbi N, Mari M, Nebout M, Fiorini C, Fénichel P, Hofman P, Poujeol P, Mograbi B. Control of the autophagy maturation step by the MAPK ERK and p38: lessons from environmental carcinogens. Autophagy 2007; 3: 57-59 [PMID: 17102581]
92. Keil E, Höcker R, Schuster M, Essmann F, Ueffing N, Hoffman B, Liebermann DA, Pfeffer K, Schulze-Osthoff K, Schmitz I. Phosphorylation of Atg5 by the Gadd45β-MEKK4-p38 pathway inhibits autophagy. Cell Death Differ 2013; 20: 321-332 [PMID: 23059785 DOI: 10.1038/cdd.2012.129]
93. Jin S, White E. Tumor suppression by autophagy through the management of metabolic stress. Autophagy 2008; 4: 563-566 [PMID: 18326941]
94. Denko NC. Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nat Rev Cancer 2008; 8: 705-713 [PMID: 19143055 DOI: 10.1038/nrc2468]
95. Kroemer G, Pouyssegur J. Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell 2008; 13: 472-482 [PMID: 18538731 DOI: 10.1016/j.ccr.2008.05.005]
96. Minet E, Michel G, Mottet D, Raes M, Michiels C. Transduction pathways involved in Hypoxia-Inducible Factor-1 phosphorylation and activation. Free Radic Biol Med 2001; 31: 847-855 [PMID: 11585703 DOI: 10.1016/S0891-5849(01)00657-8]
97. Wei Y, Pattingre S, Sinha S, Bassik M, Levine B. JNK1-mediated phosphorylation of Bcl-2 regulates starvation-induced autophagy. Mol Cell 2008; 30: 678-688 [PMID: 18570871 DOI: 10.1016/j.molcel.2008.06.001]
98. Yu L, Alva A, Su H, Dutt P, Freundt E, Welsh S, Baehrecke EH, Lenardo MJ. Regulation of an ATG7-beclin 1 program of autophagic cell death by caspase-8. Science 2004; 304: 1500-1502 [PMID: 15131264 DOI: 10.1126/science.1096645]
99. Rane MJ, Coxon PY, Powell DW, Webster R, Klein JB, Pierce W, Ping P, McLeish KR. p38 Kinase-dependent MAPKAPK-2 activation functions as 3-phosphoinositide-dependent kinase-2 for Akt in human neutrophils. J Biol Chem 2001; 276: 3517-3523 [PMID: 11042204 DOI: 10.1074/jbc.M005953200]
100. Perdiguero E, Ruiz-Bonilla V, Serrano AL, Muñoz-Cánoves P. Genetic deficiency of p38alpha reveals its critical role in myoblast cell cycle exit: the p38alpha-JNK connection. Cell Cycle 2007; 6: 1298-1303 [PMID: 17534150 DOI: 10.4161/cc.6.11.4315]
101. Waterston RH, Lindblad-Toh K, Birney E, Rogers J, Abril JF, Agarwal P, Agarwala R, Ainscough R, Alexandersson M, An P, Antonarakis SE, Attwood J, Baertsch R, Bailey J, Barlow K, Beck S, Berry E, Birren B, Bloom T, Bork P, Botcherby M, Bray N, Brent MR, Brown DG, Brown SD, Bult C, Burton J, Butler J, Campbell RD, Carninci P, Cawley S, Chiaromonte F, Chinwalla AT, Church DM, Clamp M, Clee C, Collins FS, Cook LL, Copley RR, Coulson A, Couronne O, Cuff J, Curwen V, Cutts T, Daly M, David R, Davies J, Delehaunty KD, Deri J, Dermitzakis ET, Dewey C, Dickens NJ, Diekhans M, Dodge S, Dubchak I, Dunn DM, Eddy SR, Elnitski L, Emes RD, Eswara P, Eyras E, Felsenfeld A, Fewell GA, Flicek P, Foley K, Frankel WN, Fulton LA, Fulton RS, Furey TS, Gage D, Gibbs RA, Glusman G, Gnerre S, Goldman N, Goodstadt L, Grafham D, Graves TA, Green ED, Gregory S, Guigó R, Guyer M, Hardison RC, Haussler D, Hayashizaki Y, Hillier LW, Hinrichs A, Hlavina W, Holzer T, Hsu F, Hua A, Hubbard T, Hunt A, Jackson I, Jaffe DB, Johnson LS, Jones M, Jones TA, Joy A, Kamal M, Karlsson EK, Karolchik D, Kasprzyk A, Kawai J, Keibler E, Kells C, Kent WJ, Kirby A, Kolbe DL, Korf I, Kucherlapati RS, Kulbokas EJ, Kulp D, Landers T, Leger JP, Leonard S, Letunic I, Levine R, Li J, Li M, Lloyd C, Lucas S, Ma B, Maglott DR, Mardis ER, Matthews L, Mauceli E, Mayer JH, McCarthy M, McCombie WR, McLaren S, McLay K, McPherson JD, Meldrim J, Meredith B, Mesirov JP, Miller W, Miner TL, Mongin E, Montgomery KT, Morgan M, Mott R, Mullikin JC, Muzny DM, Nash WE, Nelson JO, Nhan MN, Nicol R, Ning Z, Nusbaum C, O'Connor MJ, Okazaki Y, Oliver K, Overton-Larty E, Pachter L, Parra G, Pepin KH, Peterson J, Pevzner P, Plumb R, Pohl CS, Poliakov A, Ponce TC, Ponting CP, Potter S, Quail M, Reymond A, Roe BA, Roskin KM, Rubin EM, Rust AG, Santos R, Sapojnikov V, Schultz B, Schultz J, Schwartz MS, Schwartz S, Scott C, Seaman S, Searle S, Sharpe T, Sheridan A, Shownkeen R, Sims S, Singer JB, Slater G, Smit A, Smith DR, Spencer B, Stabenau A, Stange-Thomann N, Sugnet C, Suyama M, Tesler G, Thompson J, Torrents D, Trevaskis E, Tromp J, Ucla C, Ureta-Vidal A, Vinson JP, Von Niederhausern AC, Wade CM, Wall M, Weber RJ, Weiss RB, Wendl MC, West AP, Wetterstrand K, Wheeler R, Whelan S, Wierzbowski J, Willey D, Williams S, Wilson RK, Winter E, Worley KC, Wyman D, Yang S, Yang SP, Zdobnov EM, Zody MC, Lander ES. Initial sequencing and comparative analysis of the mouse genome. Nature 2002; 420: 520-562 [PMID: 12466850 DOI: 10.1038/nature01262]
102. Haigis KM, Kendall KR, Wang Y, Cheung A, Haigis MC, Glickman JN, Niwa-Kawakita M, Sweet-Cordero A, Sebolt- Leopold J, Shannon KM, Settleman J, Giovannini M, Jacks T. Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. Nat Genet 2008; 40: 600-608 [PMID: 18372904 DOI: 10.1038/ng.115]
103. Wang S, El-Deiry WS. TRAIL and apoptosis induction by TNF-family death receptors. Oncogene 2003; 22: 8628-8633 [PMID: 14634624 DOI: 10.1038/sj.onc.1207232]
104. De Robertis M, Massi E, Poeta ML, Carotti S, Morini S, Cecchetelli L, Signori E, Fazio VM. The AOM/DSS murine model for the study of colon carcinogenesis: From pathways to diagnosis and therapy studies. J Carcinog 2011; 10: 9 [PMID: 21483655 DOI: 10.4103/1477-3163.78279]
105. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90 [PMID: 21296855 DOI: 10.3322/caac.20107]
106. Hatzivassiliou G, Song K, Yen I, Brandhuber BJ, Anderson DJ, Alvarado R, Ludlam MJ, Stokoe D, Gloor SL, Vigers G, Morales T, Aliagas I, Liu B, Sideris S, Hoeflich KP, Jaiswal BS, Seshagiri S, Koeppen H, Belvin M, Friedman LS, Malek S. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 2010; 464: 431-435 [PMID: 20130576 DOI: 10.1038/nature08833]
107. Corcoran RB, Ebi H, Turke AB, Coffee EM, Nishino M, Cogdill AP, Brown RD, Della Pelle P, Dias-Santagata D, Hung KE, Flaherty KT, Piris A, Wargo JA, Settleman J, Mino-Kenudson M, Engelman JA. EGFR-mediated reactivation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov 2012; 2: 227-235 [PMID: 22448344 DOI: 10.1158/2159-8290.CD-11-0341]
108. Brunet A, Sweeney LB, Sturgill JF, Chua KF, Greer PL, Lin Y, Tran H, Ross SE, Mostoslavsky R, Cohen HY, Hu LS, Cheng HL, Jedrychowski MP, Gygi SP, Sinclair DA, Alt FW, Greenberg ME. Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science 2004; 303: 2011-2015 [PMID: 14976264 DOI: 10.1126/science.1094637]
109. Schreiber S, Feagan B, D'Haens G, Colombel JF, Geboes K, Yurcov M, Isakov V, Golovenko O, Bernstein CN, Ludwig D, Winter T, Meier U, Yong C, Steffgen J. Oral p38 mitogen-activated protein kinase inhibition with BIRB 796 for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol 2006; 4: 325-334 [PMID: 16527696 DOI: 10.1016/j.cgh.2005.11.013]
110. Pattingre S, Bauvy C, Codogno P. Amino acids interfere with the ERK1/2-dependent control of macroautophagy by controlling the activation of Raf-1 in human colon cancer HT-29 cells. J Biol Chem 2003; 278: 16667-16674 [PMID: 12609989 DOI: 10.1074/jbc.M210998200]
111. Chandarlapaty S, Sawai A, Scaltriti M, Rodrik-Outmezguine V, Grbovic-Huezo O, Serra V, Majumder PK, Baselga J, Rosen N. AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell 2011; 19: 58-71 [PMID: 21215704 DOI: 10.1016/j.ccr.2010.10.031]
112. Wen HC, Avivar-Valderas A, Sosa MS, Girnius N, Farias EF, Davis RJ, Aguirre-Ghiso JA. p38α Signaling Induces Anoikis and Lumen Formation During Mammary Morphogenesis. Sci Signal 2011; 4: ra34 [PMID: 21610252 DOI: 10.1126/scisignal.2001684]
113. Junttila MR, Li SP, Westermarck J. Phosphatase-mediated crosstalk between MAPK signaling pathways in the regulation of cell survival. FASEB J 2008; 22: 954-965 [PMID: 18039929 DOI: 10.1096/fj.06-7859rev]
114. Desagher S, Osen-Sand A, Montessuit S, Magnenat E, Vilbois F, Hochmann A, Journot L, Antonsson B, Martinou JC. Phosphorylation of bid by casein kinases I and II regulates its cleavage by caspase 8. Mol Cell 2001; 8: 601-611 [PMID: 11583622 DOI: 10.1016/S1097-2765(01)00335-5]
115. Berra E, Diaz-Meco MT, Moscat J. The activation of p38 and apoptosis by the inhibition of Erk is antagonized by the phosphoinositide 3-kinase/Akt pathway. J Biol Chem 1998; 273: 10792-10797 [PMID: 9553146 DOI: 10.1074/jbc.273.17.10792]
116. Wilhelm S, Carter C, Lynch M, Lowinger T, Dumas J, Smith RA, Schwartz B, Simantov R, Kelley S. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 2006; 5: 835-844 [PMID: 17016424 DOI: 10.1038/nrd2130]
117. Namboodiri HV, Bukhtiyarova M, Ramcharan J, Karpusas M, Lee Y, Springman EB. Analysis of imatinib and sorafenib binding to p38alpha compared with c-Abl and b-Raf provides structural insights for understanding the selectivity of inhibitors targeting the DFG-out form of protein kinases. Biochemistry 2010; 49: 3611-3618 [PMID: 20337484 DOI: 10.1021/bi100070r]
118. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64: 7099-7109 [PMID: 15466206 DOI: 10.1158/0008-5472.CAN-04-1443]
119. Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch M. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 2008; 7: 3129-3140 [PMID: 18852116 DOI: 10.1158/1535-7163.MCT-08-0013]
120. Dal Lago L, D'Hondt V, Awada A. Selected combination therapy with sorafenib: a review of clinical data and perspectives in advanced solid tumors. Oncologist 2008; 13: 845-858 [PMID: 18695262 DOI: 10.1634/theoncologist.2007-0233]
121. Grossi V, Liuzzi M, Murzilli S, Martelli N, Napoli A, Ingravallo G, Del Rio A, Simone C. Sorafenib inhibits p38α activity in colorectal cancer cells and synergizes with the DFGin inhibitor SB202190 to increase apoptotic response. Cancer Biol Ther 2012; 13: 1471-1481 [PMID: 22986232 DOI: 10.4161/cbt.22254]
122. Filomia F, De Rienzo F, Menziani MC. Insights into MAPK p38alpha DFG flip mechanism by accelerated molecular dynamics. Bioorg Med Chem 2010; 18: 6805-6812 [PMID: 20724167 DOI: 10.1016/j.bmc.2010.07.047]
123. Kufareva I, Abagyan R. Type-II kinase inhibitor docking, screening, and profiling using modified structures of active kinase states. J Med Chem 2008; 51: 7921-7932 [PMID: 19053777 DOI: 10.1021/jm8010299]
124. Montagut C, Settleman J. Targeting the RAF-MEK-ERK pathway in cancer therapy. Cancer Lett 2009; 283: 125-134 [PMID: 19217204 DOI: 10.1016/j.canlet.2009.01.022]
125. Strumberg D, Schultheis B. Regorafenib for cancer. Expert Opin Investig Drugs 2012; 21: 879-889 [PMID: 22577890 DOI: 10.1517/13543784.2012.684752]
126. Strumberg D, Scheulen ME, Schultheis B, Richly H, Frost A, Büchert M, Christensen O, Jeffers M, Heinig R, Boix O, Mross K. Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study. Br J Cancer 2012; 106: 1722-1727 [PMID: 22568966 DOI: 10.1038/bjc.2012.153]
127. Benson VS, Patnick J, Davies AK, Nadel MR, Smith RA, Atkin WS. Colorectal cancer screening: a comparison of 35 initiatives in 17 countries. Int J Cancer 2008; 122: 1357-1367 [PMID: 18033685 DOI: 10.1002/ijc.23273]
128. Katano K, Kondo A, Safaei R, Holzer A, Samimi G, Mishima M, Kuo YM, Rochdi M, Howell SB. Acquisition of resistance to cisplatin is accompanied by changes in the cellular pharmacology of copper. Cancer Res 2002; 62: 6559-6565 [PMID: 12438251]
129. Ferry KV, Hamilton TC, Johnson SW. Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells: role of ERCC1-XPF. Biochem Pharmacol 2000; 60: 1305-1313 [PMID: 11008124 DOI: 10.1016/S0006-2952(00)00441-X]
130. Roux PP, Blenis J. ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions. Microbiol Mol Biol Rev 2004; 68: 320-344 [PMID: 15187187 DOI: 10.1128/MMBR.68.2.320-344.2004]
131. Ozols RF. Ovarian cancer: new clinical approaches. Cancer Treat Rev 1991; 18 Suppl A: 77-83 [PMID: 1904312]
132. Marin JJ, Sanchez de Medina F, Castaño B, Bujanda L, Romero MR, Martinez-Augustin O, Moral-Avila RD, Briz O. Chemoprevention, chemotherapy, and chemoresistance in colorectal cancer. Drug Metab Rev 2012; 44: 148-172 [PMID: 22497631 DOI: 10.3109/03602532.2011.638303]
133. Pereira L, Igea A, Canovas B, Dolado I, Nebreda AR. Inhibition of p38 MAPK sensitizes tumour cells to cisplatin-induced apoptosis mediated by reactive oxygen species and JNK. EMBO Mol Med 2013; 5: 1759-1774 [PMID: 24115572 DOI: 10.1002/emmm.201302732]
134. Germani A, Matrone A, Grossi V, Peserico A, Sanese P, Liuzzi M, Palermo R, Murzilli S, Campese AF, Ingravallo G, Canettieri G, Tezil T, Simone C. Targeted therapy against chemoresistant colorectal cancers: Inhibition of p38α modulates the effect of cisplatin in vitro and in vivo through the tumor suppressor FoxO3A. Cancer Lett 2014; 344: 110-118 [PMID: 24215867 DOI: 10.1016/j.canlet.2013.10.035]
135. Veneroni S, Zaffaroni N, Daidone MG, Benini E, Villa R, Silvestrini R. Expression of P-glycoprotein and in vitro or in vivo resistance to doxorubicin and cisplatin in breast and ovarian cancers. Eur J Cancer 1994; 30A: 1002-1007 [PMID: 7946563]
136. Barancík M, Bohácová V, Kvackajová J, Hudecová S, Krizanová O, Breier A. SB203580, a specific inhibitor of p38-MAPK pathway, is a new reversal agent of P-glycoprotein-mediated multidrug resistance. Eur J Pharm Sci 2001; 14: 29-36 [PMID: 11457647 DOI: 10.1016/S0928-0987(01)00139-7]
137. Paillas S, Boissière F, Bibeau F, Denouel A, Mollevi C, Causse A, Denis V, Vezzio-Vié N, Marzi L, Cortijo C, Ait-Arsa I, Askari N, Pourquier P, Martineau P, Del Rio M, Gongora C. Targeting the p38 MAPK pathway inhibits irinotecan resistance in colon adenocarcinoma. Cancer Res 2011; 71: 1041-1049 [PMID: 21159664 DOI: 10.1158/0008-5472.CAN-10-2726]
138. Paillas S, Causse A, Marzi L, de Medina P, Poirot M, Denis V, Vezzio-Vie N, Espert L, Arzouk H, Coquelle A, Martineau P, Del Rio M, Pattingre S, Gongora C. MAPK14/p38α confers irinotecan resistance to TP53-defective cells by inducing survival autophagy. Autophagy 2012; 8: 1098-1112 [PMID: 22647487 DOI: 10.4161/auto.20268]
139. Medicherla S, Reddy M, Ying J, Navas TA, Li L, Nguyen AN, Kerr I, Hanjarappa N, Protter AA, Higgins LS. p38alpha-selective MAP kinase inhibitor reduces tumor growth in mouse xenograft models of multiple myeloma. Anticancer Res 2008; 28: 3827-3833 [PMID: 19189670]
140. Hideshima T, Podar K, Chauhan D, Ishitsuka K, Mitsiades C, Tai YT, Hamasaki M, Raje N, Hideshima H, Schreiner G, Nguyen AN, Navas T, Munshi NC, Richardson PG, Higgins LS, Anderson KC. p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells. Oncogene 2004; 23: 8766-8776 [PMID: 15480425 DOI: 10.1038/sj.onc.1208118]
141. Wen J, Feng Y, Huang W, Chen H, Liao B, Rice L, Preti HA, Kamble RT, Zu Y, Ballon DJ, Chang CC. Enhanced antimyeloma cytotoxicity by the combination of arsenic trioxide and bortezomib is further potentiated by p38 MAPK inhibition. Leuk Res 2010; 34: 85-92 [PMID: 19608275 DOI: 10.1016/j.leukres.2009.05.024]
142. Gill K, Singh AK, Kapoor V, Nigam L, Kumar R, Holla P, Das SN, Yadav S, Subbarao N, Mohanti BK, Dey S. Development of peptide inhibitor as a therapeutic agent against head and neck squamous cell carcinoma (HNSCC) targeting p38alpha MAP kinase. Biochim Biophys Acta 2013; 1830: 2763-2769 [PMID: 23238519 DOI: 10.1016/j.bbagen.2012.12.001]
143. Alvarado-Kristensson M, Melander F, Leandersson K, Rönnstrand L, Wernstedt C, Andersson T. p38-MAPK signals survival by phosphorylation of caspase-8 and caspase-3 in human neutrophils. J Exp Med 2004; 199: 449-458 [PMID: 14970175 DOI: 10.1084/jem.20031771]
144. Seifert A, Clarke PR. p38alpha- and DYRK1A-dependent phosphorylation of caspase-9 at an inhibitory site in response to hyperosmotic stress. Cell Signal 2009; 21: 1626-1633 [PMID: 19586613 DOI: 10.1016/j.cellsig.2009.06.009]
145. Yang SY, Miah A, Sales KM, Fuller B, Seifalian AM, Winslet M. Inhibition of the p38 MAPK pathway sensitises human colon cancer cells to 5-fluorouracil treatment. Int J Oncol 2011; 38: 1695-1702 [PMID: 21424124 DOI: 10.3892/ijo.2011.982]
146. Krajewska M, Moss SF, Krajewski S, Song K, Holt PR, Reed JC. Elevated expression of Bcl-X and reduced Bak in primary colorectal adenocarcinomas. Cancer Res 1996; 56: 2422-2427 [PMID: 8625322]
147. Placzek WJ, Wei J, Kitada S, Zhai D, Reed JC, Pellecchia M. A survey of the anti-apoptotic Bcl-2 subfamily expression in cancer types provides a platform to predict the efficacy of Bcl-2 antagonists in cancer therapy. Cell Death Dis 2010; 1: e40 [PMID: 21364647 DOI: 10.1038/cddis.2010.18]
148. Kim MJ, Choi SY, Park IC, Hwang SG, Kim C, Choi YH, Kim H, Lee KH, Lee SJ. Opposing roles of c-Jun NH2-terminal kinase and p38 mitogen-activated protein kinase in the cellular response to ionizing radiation in human cervical cancer cells. Mol Cancer Res 2008; 6: 1718-1731 [PMID: 19010820 DOI: 10.1158/1541-7786.MCR-08-0032]
149. Nelyudova A, Aksenov N, Pospelov V, Pospelova T. By blocking apoptosis, Bcl-2 in p38-dependent manner promotes cell cycle arrest and accelerated senescence after DNA damage and serum withdrawal. Cell Cycle 2007; 6: 2171-2177 [PMID: 17882791 DOI: 10.4161/cc.6.17.4610]
150. Zhang CL, Song F, Zhang J, Song QH. Hypoxia-induced Bcl-2 expression in endothelial cells via p38 MAPK pathway. Biochem Biophys Res Commun 2010; 394: 976-980 [PMID: 20307495 DOI: 10.1016/j.bbrc.2010.03.102]
151. Hawk ET, Viner JL, Umar A. Non-steroidal anti-inflammatory and cyclooxygenase-2-selective inhibitors in clinical cancer prevention trials. Prog Exp Tumor Res 2003; 37: 210-242 [PMID: 12795057]
152. Greenhough A, Smartt HJ, Moore AE, Roberts HR, Williams AC, Paraskeva C, Kaidi A. The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis 2009; 30: 377-386 [PMID: 19136477 DOI: 10.1093/carcin/bgp014]
153. Limami Y, Pinon A, Leger DY, Mousseau Y, Cook-Moreau J, Beneytout JL, Delage C, Liagre B, Simon A. HT-29 colorectal cancer cells undergoing apoptosis overexpress COX-2 to delay ursolic acid-induced cell death. Biochimie 2011; 93: 749-757 [PMID: 21251952 DOI: 10.1016/j.biochi.2011.01.003]
154. Marengo B, De Ciucis CG, Ricciarelli R, Furfaro AL, Colla R, Canepa E, Traverso N, Marinari UM, Pronzato MA, Domenicotti C. p38MAPK inhibition: a new combined approach to reduce neuroblastoma resistance under etoposide treatment. Cell Death Dis 2013; 4: e589 [PMID: 23579276 DOI: 10.1038/cddis.2013.118]
155. Dolado I, Nebreda A. Regulation of Tumorigenesis by p38α MAP Kinase. In: Posas F, Nebreda A, editors. Stress-Activated Protein Kinases. Berlin Heidelberg: Springer, 2008: 99-128
156. Gout S, Morin C, Houle F, Huot J. Death receptor-3, a new E-Selectin counter-receptor that confers migration and survival advantages to colon carcinoma cells by triggering p38 and ERK MAPK activation. Cancer Res 2006; 66: 9117-9124 [PMID: 16982754 DOI: 10.1158/0008-5472.CAN-05-4605]
157. Suarez-Cuervo C, Merrell MA, Watson L, Harris KW, Rosenthal EL, Väänänen HK, Selander KS. Breast cancer cells with inhibition of p38alpha have decreased MMP-9 activity and exhibit decreased bone metastasis in mice. Clin Exp Metastasis 2004; 21: 525-533 [PMID: 15679050]
158. Dhillon AS, Hagan S, Rath O, Kolch W. MAP kinase signalling pathways in cancer. Oncogene 2007; 26: 3279-3290 [PMID: 17496922]
159. Lin SP, Lee YT, Wang JY, Miller SA, Chiou SH, Hung MC, Hung SC. Survival of cancer stem cells under hypoxia and serum depletion via decrease in PP2A activity and activation of p38-MAPKAPK2-Hsp27. PLoS One 2012; 7: e49605 [PMID: 23185379]
160. Chen SF, Nieh S, Jao SW, Liu CL, Wu CH, Chang YC, Yang CY, Lin YS. Quercetin suppresses drug-resistant spheres via the p38 MAPK-Hsp27 apoptotic pathway in oral cancer cells. PLoS One 2012; 7: e49275 [PMID: 23152886]
161. Lin SP, Lee YT, Yang SH, Miller SA, Chiou SH, Hung MC, Hung SC. Colon cancer stem cells resist antiangiogenesis therapy-induced apoptosis. Cancer Lett 2013; 328: 226-234 [PMID: 23017941 DOI: 10.1016/j.canlet.2012.08.036]
162. Chiacchiera F, Simone C. The AMPK-FoxO3A axis as a target for cancer treatment. Cell Cycle 2010; 9: 1091-1096 [PMID: 20190568 DOI: 10.4161/cc.9.6.11035]
163. Rampino N, Yamamoto H, Ionov Y, Li Y, Sawai H, Reed JC, Perucho M. Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. Science 1997; 275: 967-969 [PMID: 9020077 DOI: 10.1126/science.275.5302.967]
164. Lee MR, Dominguez C. MAP kinase p38 inhibitors: clinical results and an intimate look at their interactions with p38alpha protein. Curr Med Chem 2005; 12: 2979-2994 [PMID: 16378500 DOI: 10.2174/092986705774462914]
165. Eli Lilly. A Phase 1 Study of an Oral p38 MAPK Inhibitor in Patients with Advanced Cancer In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2014 Jan 21]. Available from: URL: http://clinicaltrials.gov/archive/NCT01393990 NLM Identifier:NCT01393990